JB
NDRM

Julian Baker’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Julian Baker’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-571,667
Closed -$22.2M – 128
2017
Q3 		$22.2M Hold
571,667
– – 0.18% 38
2017
Q2 		$17.1M Hold
571,667
– – 0.15% 35
2017
Q1 		$15.2M Hold
571,667
– – 0.12% 36
2016
Q4 		$12.7M Buy
571,667
+266,667
+87% +$4.99M 0.12% 44
2016
Q3 		$5.64M Hold
305,000
– – 0.05% 68
2016
Q2 		$4.96M Hold
305,000
– – 0.05% 74
2016
Q1 		$4.31M Hold
305,000
– – 0.05% 75
2015
Q4 		$5.2M Hold
305,000
– – 0.04% 76
2015
Q3 		$6.3M Buy
305,000
+55,000
+22% +$1.13M 0.06% 72
2015
Q2 		$3.84M Hold
250,000
– – 0.03% 85
2015
Q1 		$3.35M Hold
250,000
– – 0.03% 88
2014
Q4 		$3.51M Buy
+250,000
New +$1.98M 0.04% 84

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $1.15B AUM 24.81% 1-Year Est. Return

Julian Baker's NDRM Position: Q4 2017 in Review

Julian Baker sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 571,667 shares — an estimated $22.2M sold.

Julian Baker first reported a position in NDRM in Q4 2014 and held it in 12 quarters. The position peaked at $22.2M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Julian Baker reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Julian Baker sold 571,667 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $22.2M.
  • Julian Baker first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2014 and held it in 12 quarters.
  • Julian Baker's NeuroDerm Ltd. Ordinary Shares position peaked at $22.2M in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.